These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9364979

  • 21. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L, Zhao SP, Zhou HN, Li QZ, Li JX.
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
    [Abstract] [Full Text] [Related]

  • 22. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 23. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
    Freyberger H, Schifferdecker E, Schatz H.
    Med Klin (Munich); 1994 Nov 15; 89(11):594-7, 633. PubMed ID: 7815987
    [Abstract] [Full Text] [Related]

  • 24. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul 15; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 25. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G, Irish A, Chan D, Watts G.
    Am J Kidney Dis; 2007 Jun 15; 49(6):776-85. PubMed ID: 17533020
    [Abstract] [Full Text] [Related]

  • 26. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
    Wallnöfer AE, van Griensven JM, Schoemaker HC, Cohen AF, Lambert W, Kluft C, Meijer P, Kooistra T.
    Thromb Haemost; 1993 Dec 20; 70(6):1005-8. PubMed ID: 8165591
    [Abstract] [Full Text] [Related]

  • 27. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
    Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, Coppola R, Bottasso B, Borghi MO, Gregorini L.
    Br J Haematol; 2004 Jul 20; 126(1):85-92. PubMed ID: 15198737
    [Abstract] [Full Text] [Related]

  • 28. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Jul 20; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 29. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 30. Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells.
    Nordt TK, Lutzi S, Ruef J, Peter K, Klar E, Kübler W, Sobel BE, Bode C.
    Thromb Haemost; 2001 Nov 15; 86(5):1305-13. PubMed ID: 11816722
    [Abstract] [Full Text] [Related]

  • 31. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.
    Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P.
    Arterioscler Thromb Vasc Biol; 1996 Apr 15; 16(4):511-6. PubMed ID: 8624772
    [Abstract] [Full Text] [Related]

  • 32. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.
    Wien Klin Wochenschr; 2001 Feb 15; 113(3-4):113-8. PubMed ID: 11253736
    [Abstract] [Full Text] [Related]

  • 33. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
    Roglans N, Bellido A, Rodríguez C, Cabrero A, Novell F, Ros E, Zambón D, Laguna JC.
    Clin Pharmacol Ther; 2002 Dec 15; 72(6):692-701. PubMed ID: 12496750
    [Abstract] [Full Text] [Related]

  • 34. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
    Deepa R, Velmurugan K, Saravanan G, Dwarakanath V, Agarwal S, Mohan V.
    J Assoc Physicians India; 2002 Jul 15; 50():901-6. PubMed ID: 12126344
    [Abstract] [Full Text] [Related]

  • 35. Homocysteine elevation with fibrates: is it a class effect?
    Harats D, Yodfat O, Doolman R, Gavendo S, Marko D, Shaish A, Sela BA.
    Isr Med Assoc J; 2001 Apr 15; 3(4):243-6. PubMed ID: 11344833
    [Abstract] [Full Text] [Related]

  • 36. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
    Bröijersén A, Hamsten A, Silveira A, Fatah K, Goodall AH, Eriksson M, Angelin B, Hjemdahl P.
    Thromb Haemost; 1996 Aug 15; 76(2):171-6. PubMed ID: 8865525
    [Abstract] [Full Text] [Related]

  • 37. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb 15; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 38. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
    Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM.
    Circulation; 2006 Apr 11; 113(14):1753-9. PubMed ID: 16585388
    [Abstract] [Full Text] [Related]

  • 39. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W.
    Med Sci Monit; 2000 Apr 11; 6(4):684-91. PubMed ID: 11208392
    [Abstract] [Full Text] [Related]

  • 40. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
    Piatkowska M, Kotschy M, Nartowicz E, Rajewski W.
    Pol Merkur Lekarski; 1997 Jan 11; 2(9):205-7. PubMed ID: 10907030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.